Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: BECKERS
Liczba odnalezionych rekordów: 1



Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku

1/1

Tytuł oryginału: Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in the management of acromegaly.
Autorzy: Caron Ph., Beckers A., Cullen D. R., Goth M. I., Gutt B., Laurberg P., Pico A. M., Valimaki M., Zgliczyński W.
Źródło: J. Clin. Endocrinol. Metab. 2002: 87 (1) s.99-104, il., tab., bibliogr. 22 poz.
Sygnatura GBL: 310,620

Hasła klasyfikacyjne GBL:
  • endokrynologia
  • farmacja

    Typ dokumentu:
  • praca kliniczna
  • praca opublikowana za granicą
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie

    Streszczenie angielskie: Lanreotide Autogel is a new long-acting aqueous preparation of lanreotide for the treatment of acromegaly and is administered by deep sc injection from a small volume, prefilled syringe. The aim of this study was to evaluate the efficacy and safety of this new ong-acting formulation in a large population of acromegalic patients previously responsive to lanreotide 30 mg, im (substained release microparticle formulation). Lanreotide Autogel was administered by deep sc injection every 28 d to 107 patients (54 males and 53 females; mean age, 54 ń 1.2 yr). All patients had been treated with lanreotide (30 mg) for at least 3 months before study entry and had a mean GH level less than 10 ng/ml after at least 4 subsequent im injections every 14 d (48 p.c.), 10 d (32 p.c.), or 7 d (20 p.c.). Treatment was switched from lanreotide 30 mg injected every 14, 10, or 7 d to 60, 90, or 120 mg lanreotide Autogel, respectively, every 28 d. After three fixed dose injections of lanreotide Autogel, mean lanreotide levels were similar to those obtained at steady state with lanreotide 30 mg. During lanreotide Autogel treatment, the control of acromegalic symptoms was comparable with that previoulsy achived during lanreotide 30 mg treatment. After 3 injections of lanreotide Autogel, mean GH (2.87 ń 0.22 ng/ml) and IGF-I (317 ń 15 ng/ml) values were comparable with those recorded at the end of lanreotide 30 mg treatment (GH, 2.82 ń 0.19 ng/ml; IGF-I, 323 ń 16 ng/ml). GH levels below 2.5 ng/ml and age-/sex-normalized IGF-I were achived in 33 p.c. and 39 p.c. of patients during lanreotide 30 mg and lanreotide Autogel treatment, respectively...

    stosując format: